Skip to main content
NASDAQ:GANX

Gain Therapeutics Competitors

$9.37
+0.37 (+4.11 %)
(As of 05/14/2021 11:50 AM ET)
Add
Compare
Today's Range
$9.37
$9.76
50-Day Range
$9.78
$15.80
52-Week Range
$8.75
$17.93
Volume151 shs
Average Volume104,890 shs
Market Capitalization$111.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Gain Therapeutics (NASDAQ:GANX) Vs. SGTX, ANGN, LABP, RAIN, NEXI, and TERN

Should you be buying GANX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Gain Therapeutics, including Sigilon Therapeutics (SGTX), Angion Biomedica (ANGN), Landos Biopharma (LABP), Rain Therapeutics (RAIN), NexImmune (NEXI), and Terns Pharmaceuticals (TERN).

Gain Therapeutics (NASDAQ:GANX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gain Therapeutics and Sigilon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gain Therapeutics00203.00
Sigilon Therapeutics01302.75

Gain Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 220.17%. Sigilon Therapeutics has a consensus target price of $53.75, indicating a potential upside of 305.66%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Gain Therapeutics.

Earnings and Valuation

This table compares Gain Therapeutics and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain TherapeuticsN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Gain Therapeutics and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gain TherapeuticsN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Sigilon Therapeutics beats Gain Therapeutics on 2 of the 3 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Profitability

This table compares Angion Biomedica and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Angion BiomedicaN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Angion Biomedica and Gain Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Angion Biomedica00403.00
Gain Therapeutics00203.00

Angion Biomedica currently has a consensus price target of $59.3333, indicating a potential upside of 316.67%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Angion Biomedica's higher possible upside, equities analysts clearly believe Angion Biomedica is more favorable than Gain Therapeutics.

Earnings & Valuation

This table compares Angion Biomedica and Gain Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Angion BiomedicaN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Summary

Angion Biomedica beats Gain Therapeutics on 2 of the 2 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Landos Biopharma and Gain Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Landos Biopharma01302.75
Gain Therapeutics00203.00

Landos Biopharma presently has a consensus price target of $25.50, indicating a potential upside of 147.57%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Landos Biopharma.

Valuation & Earnings

This table compares Landos Biopharma and Gain Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landos BiopharmaN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Landos Biopharma and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Landos BiopharmaN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Summary

Gain Therapeutics beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Rain Therapeutics (NASDAQ:RAIN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Rain Therapeutics and Gain Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rain Therapeutics0000N/A
Gain Therapeutics00203.00

Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Rain Therapeutics.

Valuation & Earnings

This table compares Rain Therapeutics and Gain Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rain TherapeuticsN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Rain Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rain TherapeuticsN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Summary

Gain Therapeutics beats Rain Therapeutics on 2 of the 2 factors compared between the two stocks.

NexImmune (NASDAQ:NEXI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Profitability

This table compares NexImmune and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NexImmuneN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for NexImmune and Gain Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NexImmune00303.00
Gain Therapeutics00203.00

NexImmune currently has a consensus price target of $33.3333, suggesting a potential upside of 94.36%. Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 220.17%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than NexImmune.

Valuation & Earnings

This table compares NexImmune and Gain Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NexImmuneN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Terns Pharmaceuticals (NASDAQ:TERN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Profitability

This table compares Terns Pharmaceuticals and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Terns PharmaceuticalsN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Terns Pharmaceuticals and Gain Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Terns Pharmaceuticals and Gain Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Terns Pharmaceuticals00303.00
Gain Therapeutics00203.00

Terns Pharmaceuticals currently has a consensus price target of $30.50, indicating a potential upside of 90.74%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Terns Pharmaceuticals.


Gain Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SGTX
Sigilon Therapeutics
1.4$13.25+6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24+1.7%$412.78 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.30+1.0%$409.20 millionN/A0.00
RAIN
Rain Therapeutics
1.3$15.23+1.0%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.15+7.7%$390.30 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.99+5.2%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.42+8.5%$370.65 millionN/A0.00News Coverage
Gap Up
PRTG
Portage Biotech
0.0$28.65+2.1%$338.81 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$11.55+0.4%$319.45 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.65+5.7%$312.00 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
IMPL
Impel NeuroPharma
0.3$13.84+0.8%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.40+9.1%$247.46 millionN/A-2.53
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.31+1.2%$233.40 millionN/A-2.29Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34+1.0%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.08+0.9%$193.93 millionN/A0.00Quiet Period Expiration
Gap Up
Annovis Bio logo
ANVS
Annovis Bio
1.7$24.23+3.9%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$6.99+8.6%$159.12 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.85+4.5%$143.77 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.15+1.9%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60+6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.66+0.0%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$18.16+8.6%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.41+6.2%$37.69 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.27+11.9%$31.70 millionN/A0.00Upcoming Earnings
News Coverage
MYMD
MyMD Pharmaceuticals
0.0$3.64+0.0%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71+1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85+2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18+3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.95+16.5%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.32+0.4%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.53+6.5%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.